Septerna, INC

Septerna, Inc. announced its second quarter 2026 financial results and business highlights, reporting a cash position of $516.5 million and ongoing progress in its clinical trials for SEP-479.

Septerna, Inc. announced the election of two new directors and the ratification of Ernst & Young LLP as its independent auditor for the fiscal year 2026 following its annual meeting of stockholders.

Septerna, Inc. announced its first quarter 2026 financial results and business highlights, reporting significant pipeline progress with positive Phase 1 data for SEP-631 and initiation of a Phase 1 trial for SEP-479, while maintaining a strong cash position.

Septerna, Inc. has dosed the first participants in a Phase 1 clinical trial for SEP-479, an oral small molecule agonist for hypoparathyroidism, with data expected in late 2026 or early 2027.

Septerna, Inc. announced positive Phase 1 clinical trial results for SEP-631, an oral drug for mast cell-driven diseases, and outlined its Phase 2 development strategy.

Septerna, Inc. presented updates on its lead GPCR drug programs, including SEP-479 and SEP-631, and highlighted its Novo Nordisk collaboration, projecting a cash runway into 2029.

Septerna, Inc. reported its first-quarter 2026 financial results, highlighting progress in its clinical-stage drug development programs and a significant increase in revenue driven by its collaboration with Novo Nordisk.

Septerna reported a net income of $8.2 million for Q3 2025, primarily driven by a $195 million upfront payment from Novo Nordisk and a $12.5 million milestone from Vertex, while advancing new drug candidates SEP-479 and SEP-631.

Septerna, Inc. reports increased losses but secures a transformative collaboration with Novo Nordisk, significantly extending its cash runway and validating its drug discovery platform.

Septerna, Inc. announces its financial results for the first quarter of 2025 and highlights a new global collaboration with Novo Nordisk A/S.

Septerna Inc., a clinical-stage biotechnology company, reported a net loss of $20.5 million for the third quarter of 2024, with significant increases in research and development expenses.

Septerna's 10-K filing details a strategic shift in their hypoparathyroidism program following adverse events in a Phase 1 trial, alongside updates on their broader GPCR-targeted drug development pipeline.

Third Rock Ventures V, L.P. and 5 others reported changes in beneficial ownership of Septerna, Inc. common stock on August 12, 2026.

Ra Capital Management, L.P. and 4 others reported changes in beneficial ownership of Septerna, Inc. common stock on August 12, 2026.

Elizabeth Bhatt, President and COO of Septerna, Inc., sold 25,000 shares of common stock on August 11, 2026 for $44.00 per share.

Daniel D. Long, SVP, Drug Discovery of Septerna, Inc., sold 3,334 shares of common stock on August 3, 2026.

Elizabeth Bhatt, President and COO of Septerna, Inc., sold 4,000 shares of common stock on July 15, 2026 for $33.99 per share.

Septerna Inc. SVP Daniel D. Long sold company stock valued at over $100,000 through a pre-arranged 10b5-1 plan, while also acquiring shares via stock options.

Septerna, Inc. announces its 2026 Annual Meeting of Stockholders to be held virtually on June 26, 2026.

Septerna, Inc. will hold its 2025 Annual Meeting of Stockholders online on June 17, 2025, with voting open until June 16, 2025.

Septerna, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Septerna, Inc. is increasing the number of shares offered in its initial public offering by 830,556 shares, including an underwriter option, through a Form S-1 filing with the SEC.

Septerna, a clinical-stage biotech firm, is seeking to raise $250 million through an initial public offering to further the development of its oral small molecule GPCR-targeted drug pipeline.

Septerna, Inc. files an amended S-1/A form detailing changes to its bylaws, particularly regarding stockholder meetings and director nominations, as it prepares for its initial public offering.

Septerna, Inc. files an S-1 registration statement, detailing an amended investors' rights agreement in preparation for its initial public offering.

RA Capital Management, L.P. and affiliated entities have amended their Schedule 13D filing to report a combined beneficial ownership of 11.8% of Septerna, Inc.'s common stock.

Driehaus Capital Management LLC has amended its Schedule 13G filing to report an increased beneficial ownership of Septerna, Inc. common stock to 9.83%.

Driehaus Capital Management LLC has increased its beneficial ownership in Septerna, Inc. to 10.46% as of May 31, 2025, up from 7.03% reported on March 31, 2025.

Multiple entities associated with Biotechnology Value Fund, including BVF Partners L.P. and Mark N. Lampert, have disclosed a combined beneficial ownership of 9.9% of Septerna, Inc.'s common stock as of March 31, 2025.

Driehaus Capital Management LLC has filed an amended Schedule 13G, disclosing an increased beneficial ownership in Septerna, Inc. to 7.03% as of March 31, 2025, up from 5.83% at the end of 2024.

Third Rock Ventures V, L.P. and Third Rock Ventures VI, L.P., along with their respective general partners, have filed an amended Schedule 13G disclosing beneficial ownership of 14.0% and 9.5% respectively, in Septerna, Inc.'s common stock.

Driehaus Capital Management LLC has reported a passive beneficial ownership of 5.83% in Septerna, Inc.'s common stock as of December 31, 2024, through a Schedule 13G filing with the SEC.